about
The effects of antiepileptic drugs on cognitive functional magnetic resonance imagingEffects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals.Behaviour, cognition and epilepsy.Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.Cognitive Effects of Low-dose Topiramate Compared with Oxcarbazepine in Epilepsy PatientsReview of topiramate for the treatment of epilepsy in elderly patients.Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control studyClinical experience with open-label topiramate use in infants younger than 2 years of age.The cognitive impact of antiepileptic drugs.Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders.Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort StudySafety and tolerability of emerging pharmacological treatments for bipolar disorder.Determinants of outcome in childhood epilepsy.Topiramate and its clinical applications in epilepsy.Topiramate in the treatment of partial and generalized epilepsy.Psychopharmacology of topiramate: from epilepsy to bipolar disorder.Efficacy and Safety of Topiramate for Essential Tremor: A Meta-Analysis of Randomized Controlled TrialsThe effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memoryPharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers.Combination phentermine/topiramate for obesity treatment in primary care: a review.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Attention-deficit/hyperactivity disorder symptoms in adults with self-reported epilepsy: Results from a national epidemiologic survey of epilepsy.Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?Postmarketing Results: Useful, But Proceed with CautionEfficacy and Tolerability of Second and Third Generation Anti-epileptic Drugs in Refractory Epilepsy: A Network Meta-Analysis.Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis.Effectiveness of topiramate in the prevention of childhood headaches.The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy.Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures.Language disturbances as a side effect of prophylactic treatment of migraine.The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice.
P2860
Q27005706-60370F62-70AD-4641-8401-B3265B661354Q30441589-42ACCF3C-1A93-40CC-BB9E-1B65AE27CDFBQ31026691-6627AE5E-D555-43BF-A17F-6CAE64D6EA12Q33202111-F1DF2DCB-67CD-4AA1-B532-ADFFF7B7DD63Q33790784-DBF778EE-24D6-435C-98FC-A066E2602195Q33819386-5DA149B7-2AD7-4EC2-A74D-5BF129437C0EQ34053280-509F3302-7666-4AD6-860C-767BDA69123AQ35132987-85F061AB-5D90-4A2C-A573-2256AA7350BFQ35588407-DF75AF8E-A700-46E5-AEE3-704D27260C0BQ35618437-6660109A-1765-43F2-825B-616965D24EE0Q35684007-5FC6A7B1-B440-486B-A2B2-7CEC4BBF36D9Q36199036-086BE4B1-1F94-45A6-BA78-89481B5E466DQ36344184-655AA188-7876-43E3-8DEE-FC9CDA7C8E16Q36429751-0C1C9650-C772-481D-B041-ED1EF3D1C7E1Q37129817-5E34AE06-6837-486A-9A55-6EF9BA40CCFBQ37166152-C6AF4EE2-3D31-4E65-9844-5F94AB816109Q37176201-C212776F-679F-4B93-9A4F-F266FB317386Q37244159-41521104-5520-41D1-BAB3-B8BF45611C07Q37666090-B8DFDA5A-F45B-46A3-B807-B7A457406652Q38200830-C74CB134-8135-438F-B35A-C4DAD2C5D581Q38826206-ECE0A912-E2FC-4F20-9B87-E56939CF6475Q39056793-44A2B647-FA1B-4B58-8E5C-9D8127A51994Q39107282-C3F5D3A6-65A3-4F84-95D0-EF9A6B766008Q40467788-46FC5A5F-7951-4A8E-9F03-2BEB3F705DAEQ42113049-CC55856F-FAC8-408B-8C81-194F0599E549Q42371898-75EE959C-8FDF-4CA2-897C-9F7369B7365FQ44187285-D5137F46-7AF7-4F06-B9C6-99CCCC5866FDQ44667891-222C9F3D-E85E-4FDE-92D7-9DFF6F2B94D2Q46735559-243CABCF-43B1-44AF-90EF-433BF78EE615Q46816148-82CC1858-24A6-4E2B-927D-BDCC7FD07FE7Q48598083-1B1FC17B-1713-463B-BC29-FD609234413B
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Postmarketing experience with topiramate and cognition.
@en
Postmarketing experience with topiramate and cognition.
@nl
type
label
Postmarketing experience with topiramate and cognition.
@en
Postmarketing experience with topiramate and cognition.
@nl
prefLabel
Postmarketing experience with topiramate and cognition.
@en
Postmarketing experience with topiramate and cognition.
@nl
P2093
P2860
P1433
P1476
Postmarketing experience with topiramate and cognition.
@en
P2093
G L Morris
J Liporace
PADS Investigators. Post-marketing antiepileptic drug survey
P2860
P304
P356
10.1046/J.1528-1157.2001.41700.X
P577
2001-09-01T00:00:00Z